Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 9 studies | 35% ± 14% | |
oligodendrocyte precursor cell | 8 studies | 38% ± 15% | |
macrophage | 8 studies | 33% ± 14% | |
fibroblast | 6 studies | 21% ± 6% | |
myeloid cell | 6 studies | 24% ± 6% | |
type II pneumocyte | 6 studies | 24% ± 8% | |
endothelial cell | 5 studies | 25% ± 9% | |
microglial cell | 5 studies | 21% ± 4% | |
astrocyte | 5 studies | 21% ± 6% | |
dendritic cell | 5 studies | 20% ± 7% | |
B cell | 4 studies | 27% ± 6% | |
plasma cell | 4 studies | 28% ± 10% | |
epithelial cell | 4 studies | 26% ± 10% | |
brush cell | 4 studies | 37% ± 16% | |
club cell | 4 studies | 32% ± 17% | |
mast cell | 3 studies | 23% ± 6% | |
hepatocyte | 3 studies | 48% ± 25% | |
endothelial cell of lymphatic vessel | 3 studies | 23% ± 4% | |
monocyte | 3 studies | 27% ± 5% | |
pericyte | 3 studies | 22% ± 8% | |
goblet cell | 3 studies | 32% ± 15% | |
smooth muscle cell | 3 studies | 18% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 4 studies | 23% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 2326.35 | 245 / 245 | 100% | 8.36 | 501 / 502 |
breast | 100% | 2125.43 | 459 / 459 | 100% | 7.67 | 1113 / 1118 |
intestine | 100% | 2434.50 | 966 / 966 | 99% | 6.71 | 523 / 527 |
lung | 100% | 5739.26 | 578 / 578 | 99% | 7.14 | 1144 / 1155 |
bladder | 100% | 2064.38 | 21 / 21 | 99% | 7.06 | 499 / 504 |
esophagus | 100% | 2198.75 | 1445 / 1445 | 99% | 6.71 | 181 / 183 |
stomach | 100% | 2100.89 | 359 / 359 | 99% | 7.04 | 282 / 286 |
thymus | 100% | 4041.73 | 653 / 653 | 99% | 8.51 | 596 / 605 |
liver | 100% | 2380.63 | 226 / 226 | 98% | 6.07 | 399 / 406 |
uterus | 100% | 2434.74 | 170 / 170 | 98% | 5.85 | 451 / 459 |
kidney | 100% | 1380.36 | 89 / 89 | 98% | 5.33 | 879 / 901 |
pancreas | 100% | 1768.70 | 327 / 328 | 96% | 6.37 | 171 / 178 |
skin | 100% | 2092.98 | 1807 / 1809 | 95% | 11.72 | 447 / 472 |
ovary | 100% | 1446.60 | 180 / 180 | 93% | 3.94 | 402 / 430 |
brain | 64% | 479.57 | 1696 / 2642 | 82% | 4.95 | 579 / 705 |
adrenal gland | 100% | 1400.50 | 257 / 258 | 26% | 0.88 | 59 / 230 |
adipose | 100% | 2321.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3087.97 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 3625.36 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.57 | 1 / 1 |
muscle | 100% | 3615.93 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 98% | 1945.10 | 846 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 9.80 | 28 / 29 |
tonsil | 0% | 0 | 0 / 0 | 96% | 4.50 | 43 / 45 |
peripheral blood | 86% | 2388.33 | 800 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 83% | 6.50 | 66 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035278 | Biological process | miRNA-mediated gene silencing by inhibition of translation |
GO_0033962 | Biological process | P-body assembly |
GO_0007010 | Biological process | cytoskeleton organization |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0035331 | Biological process | negative regulation of hippo signaling |
GO_0035195 | Biological process | miRNA-mediated post-transcriptional gene silencing |
GO_0001666 | Biological process | response to hypoxia |
GO_0045668 | Biological process | negative regulation of osteoblast differentiation |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0008360 | Biological process | regulation of cell shape |
GO_0016310 | Biological process | phosphorylation |
GO_0002076 | Biological process | osteoblast development |
GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
GO_0016477 | Biological process | cell migration |
GO_0005886 | Cellular component | plasma membrane |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005925 | Cellular component | focal adhesion |
GO_0000932 | Cellular component | P-body |
GO_0005829 | Cellular component | cytosol |
GO_0005912 | Cellular component | adherens junction |
GO_0005737 | Cellular component | cytoplasm |
GO_0016442 | Cellular component | RISC complex |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0003714 | Molecular function | transcription corepressor activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | LIMD1 |
Protein name | LIM domain-containing protein 1 |
Synonyms | |
Description | FUNCTION: Adapter or scaffold protein which participates in the assembly of numerous protein complexes and is involved in several cellular processes such as cell fate determination, cytoskeletal organization, repression of gene transcription, cell-cell adhesion, cell differentiation, proliferation and migration. Positively regulates microRNA (miRNA)-mediated gene silencing and is essential for P-body formation and integrity. Acts as a hypoxic regulator by bridging an association between the prolyl hydroxylases and VHL enabling efficient degradation of HIF1A. Acts as a transcriptional corepressor for SNAI1- and SNAI2/SLUG-dependent repression of E-cadherin transcription. Negatively regulates the Hippo signaling pathway and antagonizes phosphorylation of YAP1. Inhibits E2F-mediated transcription, and suppresses the expression of the majority of genes with E2F1-responsive elements. Regulates osteoblast development, function, differentiation and stress osteoclastogenesis. Enhances the ability of TRAF6 to activate adapter protein complex 1 (AP-1) and negatively regulates the canonical Wnt receptor signaling pathway in osteoblasts. May act as a tumor suppressor by inhibiting cell proliferation. . |
Accessions | ENST00000440097.5 ENST00000273317.5 Q9UGP4 C9JRJ5 |